Genetic variation in B cell–activating factor of the TNF family (BAFF) and asthma exacerbations among African American subjects

Abstract B-cell activating factor (BAFF) single nucleotide polymorphisms (SNPs) are associated with autoimmune diseases. Because patients with classic and overlap chronic GVHD (cGVHD) have features of autoimmune diseases, we studied the association of recipient and/or donor BAFF SNPs with the phenotype of GVHD after allogeneic stem cell transplantation. Twenty tagSNPs of the BAFF gene were genotyped in 164 recipient/donor pairs. GVHD after day 100 occurred in 124 (76%) patients: acute GVHD (aGVHD) subtypes (n = 23), overlap GVHD (n = 29), and classic cGVHD (n = 72). In SNP analyses, 9 of the 20 tag SNPs were significant comparing classic/overlap cGVHD versus aGVHD subtypes/no GVHD. In multivariate analyses, 4 recipient BAFF SNPs (rs16972217 [odds ratio = 2.72, P = .004], rs7993590 [odds ratio = 2.35, P = .011], rs12428930 [odds ratio2.53, P = .008], and rs2893321 [odds ratio = 2.48, P = .009]) were independent predictors of GVHD subtypes, adjusted for conventional predictors of cGVHD. This study shows that genetic variation of BAFF modulates GVHD phenotype after allogeneic stem cell transplantation.

Download Full-text

Faculty Opinions recommendation of Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1160897.627349 ◽

2009 ◽

Author(s):

Sarah Gaffen ◽

Allen Ho

Keyword(s):

Systemic Lupus Erythematosus ◽

B Cell ◽

Lupus Erythematosus ◽

Cell Biology ◽

Interleukin 17 ◽

Systemic Lupus ◽

B Cell Activating Factor

Download Full-text

Faculty Opinions recommendation of Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.719555197.793546484 ◽

2018 ◽

Author(s):

David Hayes

Keyword(s):

Tumor Necrosis Factor ◽

B Cell ◽

Family Member ◽

Tumor Necrosis ◽

Intrinsic Property ◽

Tumor Necrosis Factor Family ◽

B Cell Activating Factor ◽

Necrosis Factor

Download Full-text

B-cell activating factor BAFF as a novel alert marker for the immunological risk stratification after kidney transplantation

Immunologic Research ◽

10.1007/s12026-021-09205-4 ◽

2021 ◽

Author(s):

Antonia Margarete Schuster ◽

N. Miesgang ◽

L. Steines ◽

C. Bach ◽

B. Banas ◽

...

Keyword(s):

Kidney Transplantation ◽

B Cell ◽

Graft Function ◽

Risk Profile ◽

Kidney Transplant Recipients ◽

Post Transplantation ◽

Antibody Mediated Rejection ◽

B Cell Activating Factor ◽

Medium Risk ◽

Patients At Risk

AbstractThe B cell activating factor BAFF has gained importance in the context of kidney transplantation due to its role in B cell survival. Studies have shown that BAFF correlates with an increased incidence of antibody-mediated rejection and the development of donor-specific antibodies. In this study, we analyzed a defined cohort of kidney transplant recipients who were treated with standardized immunosuppressive regimens according to their immunological risk profile. The aim was to add BAFF as an awareness marker in the course after transplantation to consider patient’s individual immunological risk profile. Included patients were transplanted between 2016 and 2018. Baseline data, graft function, the occurrence of rejection episodes, signs of microvascular infiltration, and DSA kinetics were recorded over 3 years. BAFF levels were determined 14 d, 3 and 12 months post transplantation. Although no difference in graft function could be observed, medium-risk patients showed a clear dynamic in their BAFF levels with low levels shortly after transplantation and an increase in values of 123% over the course of 1 year. Patients with high BAFF values were more susceptible to rejection, especially antibody-mediated rejection and displayed intensified microvascular inflammation; the combination of high BAFF + DSA puts patients at risk. The changing BAFF kinetics of the medium risk group as well as the increased occurrence of rejections at high BAFF values enables BAFF to be seen as an awareness factor. To compensate the changing immunological risk, a switch from a weaker induction therapy to an intensified maintenance therapy is required.

Download Full-text